We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
3 own
8 watching
Current Price
$2.06
$0.08
(4.04%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
74.15M
52-Week High
8.54
52-Week Low
1.51
Average Volume
0.02M
Dividend Yield
--
P/E Ratio
--
Market Capitalization74.15M
52-Week High8.54
52-Week Low1.51
Average Volume0.02M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, a esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Business Wire
16days ago
Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid, the Company), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that Lishan Aklog, M.D., the Lucids Chairman and Chief Executive Officer, will...
Business Wire
17days ago
Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid, the Company), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced the commencement of production of its EsoCheck Esophageal Cell Collection...
Zolmax
2 months ago
Lucid Diagnostics Inc. (NASDAQ:LUCD Get Rating) Director Stanley Lapidus sold 33,864 shares of the businesss stock in a transaction dated Tuesday, September 20th. The shares were sold at an average price of $1.70, for a total transaction of $57,568.80. Following the completion of the sale, the ...
Business Wire
2 months ago
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a diversified commercial-stage medical device company operating in the medical device, diagnostics, and digital health sectors, today announced that Lishan Aklog, M.D., the Companys Chairman and CEO, will participate in one-on-one investor...
Business Wire
3 months ago
Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that its subsidiary, LucidDx Labs Inc. (LucidDx Labs), has launched four new Lucid Test...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$2.06
$0.08
(4.04%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00